Media Articles | ICON plc

ICON experts frequently author or contribute to industry trade press.

Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.

12 December 2024

AI’s transformative role in drug discovery and development

In the Irish Times Life Sciences and Stem supplement, ICON’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
12 December 2024

Girls see gender inequality as biggest barrier to pursuing Stem careers

Rose Kidd, President, Operations Delivery, provides an overview on how ICON is working to meet its gender balance ambitions in the Irish Times Life Sciences and Stem supplement.
12 December 2024

To advance in life sciences we must be more ambitious and prioritise public investment in research

In this article from the Irish Times Life Sciences and Stem supplement, Barry Balfe, President, ICON Pharma Solutions, outlines his views on how Ireland’s life sciences sector can continue to grow and attract investment.
09 December 2024

The move to greener clinical development

Sustainability requires a layered approach that balances operational feasibility and with greener practices. Sean Morgan, Director of Clinical Supplies Management, discusses how ICON is tackling issues like kit waste, carbon emissions and ethical supply chains.
06 December 2024

To be precise: How oncology therapies can stand out in a diverse, uncertain landscape

Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.
06 December 2024

Half of pharma and biotech companies using AI and big data

This news piece from Clinical Trials Arena provides an overview of the findings of ICON’s recent Digital Disruption survey, which found sentiment towards artificial intelligence and digital tools in the clinical research sector is positive.
05 December 2024

Outcome measures: Patients beyond endpoints

The evolving regulatory requirement to put patients at the centre of the drug development process – patient-centric from end to end – means pharmaceutical sponsors must design clinical trials with patient-centred outcomes in mind.
21 November 2024

Curated and customised outsourcing

As the outsourcing market evolves, pharmaceutical businesses are reassessing their strategies to better insulate themselves against the pressure of compounding macroeconomic constraints, including a looming patent cliff, rising costs and developmental risks.
14 November 2024

Women Mean Business (WMB) Businesswoman Award 2024

Following her receipt of the WMB Businesswoman Award 2024, Rose Kidd, President, Operations Delivery is interviewed by Women Mean Business on her role, the opportunities for the life sciences industry and her views on how we can support more women to progress STEM careers.
25 October 2024

Striking the right balance between transparency and privacy in clinical trial data sharing

In this article, our experts explore how to strike the right balance between adequately anonymising clinical trial data to protect participant privacy and company assets, while still preserving its value for research purposes (see page 16).